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AbstrAct:
Killing of proliferating normal cells limits chemotherapy of cancer. Several strategies 
to selectively protect normal cells were previously suggested. Here we further 
explored the protection of normal cells from cell cycle-specific chemotherapeutic 
agents such as mitotic inhibitors (MI). We focused on a long-term cell recovery 
(rather than on a short-term cell survival) after a 3-day exposure to MI (paclitaxel 
and nocodazole). In three normal human cell types (RPE, NKE, WI-38t cells) but 
not in cancer cells with mutant p53, pre-treatment with nutlin-3a, a non-genotoxic 
inducer of wt p53, caused G1 and/or G2 arrest, thus preventing lethal mitotic 
arrest  caused  by  MI  and  allowing  normal  cells  to  recover  after  removal  of  MI. 
Rapamycin,  an  inhibitor  of  the  nutrient-sensing  mTOR  pathway,  potentiated  the 
protective  effect  of  nutlin-3a  in  normal  cells.  Also,  a  combination  of  rapamycin 
and  metformin,  an  anti-diabetic  drug,  induced  G1  and  G2  arrest  selectively  in 
normal  cells  and  thereby  protected  them  from  MI.  A  combination  of  metformin 
and rapamycin also protected normal cells in low glucose conditions, whereas in 
contrast it was cytotoxic for cancer cells. Based on these data and the analysis 
of  the  literature,  we  suggest  that  a  rational  combination  of  metformin  and 
rapamycin  can  potentiate  chemotherapy  with  mitotic  inhibitors  against  cancer, 
while protecting normal cells, thus further increasing the therapeutic window.
IntroductIon
Microtubule-targeting agents or mitotic inhibitors 
are one of the cornerstones of modern chemotherapy [1-
5]. Despite different effects on microtubules and tubulin, 
a variety of structures and binding sites, all microtubule-
active drugs at low concentrations kill proliferating 
(cycling) cells, by causing fatal mitotic arrest [6-9]. In 
addition to killing cancer cells, these mitotic inhibitors 
(MI) can kill normal cycling cells (bone marrow cells, hair 
follicles, mucosal and epithelial cells), thus causing certain 
side effects. Side effects may not only be devastating, but 
they also limit anticancer therapy. The goal is to protect 
proliferating normal cells from the cytotoxicity of MI, 
without protecting cancer cells.
Given that MI cannot possibly cause mitotic arrest 
in the cells that do not enter mitosis, a transient G1 and/or 
G2 arrest (protective arrest) must protect cells from MI. 
How can we cause a protective G1/G2 arrest selectively in 
normal cells but not in cancer cells? Whereas all normal 
cells have wt p53, this tumor suppressor is mutant or lost 
in 50% of cancers [10]. This absence provides a means 
for selective protection of normal cells without protecting 
cancer cells lacking wt p53 [11-13]. Thus, induction of 
p53 can arrest cells in G1 and G2 phases, preventing their 
entry  into  mitosis.  Specifically,  low  concentrations  of 
DNA damaging drugs (DDD) induce wt p53 and arrest 
cells in G1 and G2, thus protecting cells from mitotic 
inhibitors [14-17]. In paired cell lines, DDD protected 
cells with wt p53 but not cells lacking p53 and p21 [14]. 
However, the effects of DDD are poorly reversible. While 
mitotic arrest and polyploidization were prevented (a 
short term protection), the prospect on long-term cell 
survival and recovery of proliferation remained unclear. 
Also DDD can protect some cancer cell lines lacking p53 
[15]. It was given consideration from the start that less Oncotarget 2011; 2:  222 - 233 223 www.impactjournals.com/oncotarget
toxic and more selective drugs should be found to induce 
p53 for the optimal protection of normal cells [14]. 
Nutlin-3a, an inhibitor of Mdm2, induces wt p53 
without causing DNA damage [18, 19]. Also, its effect is 
strictly p53-dependent [20]. In paired and isogenic cancer 
cell lines (with and without wt p53), nutlin-3a selectively 
protected cells with wt p53 [16, 21, 22]. Importantly, 
nutlin-3a provided a long-term protection from paclitaxel 
to  skin-derived  fibroblast  cell  line  in  culture,  so  that 
cells proliferated after removal of paclitaxel [21]. This 
outstanding result needed to be further confirmed in other 
normal cell types including epithelial cells.
Nutlin-3a is an experimental therapeutic and is not 
approved yet for clinical use. Therefore, we also planned 
to investigate clinically approved drugs that might protect 
normal cells from MI. Cancer cells are characterized by 
dysregulation of the PI-3K/mTOR pathway [23-26]. It 
was hypothesized that the mTOR inhibitor rapamycin may 
protect normal cells from cycle-dependent chemotherapy 
[27]. Although seemingly unrelated, a remarkable study 
by Longo and co-workers showed that fasting protected 
mice from the toxicity of chemotherapy [28-30] and, 
most importantly, abrogated side effects of chemotherapy 
in patients with cancer [31]. We suggest that protective 
effect of fasting may in part be due to inhibition of the 
nutrient-sensing mTOR pathway in normal cells.  Fasting 
decreases blood levels of nutrients (glucose, amino acids), 
IGF-1 and insulin, which otherwise activate mTOR in the 
organism [32-37]. 
Metformin, an anti-diabetic drug, can in part 
substitute for fasting because it decreases levels of glucose 
and insulin [38, 39]. Metformin deactivates mTOR in mice 
[40]. Also, metformin inhibits the mTOR pathway in cell 
culture [41-43]. Both metformin and rapalogs (rapamycin 
and its analogs) are clinically approved drugs. Rapalogs 
are also approved for cancer therapy [44, 45]. Metformin 
and rapamycin potentiate chemotherapy against cancer 
[46]. Furthermore, rapalogs and metformin in combination 
with chemotherapy (including MI) are undergoing clinical 
trials [47-50].
Here we investigated whether nutlin-3a, rapamycin, 
metformin and their combinations can protect 3 normal 
cell  types:  WI-38t  fibroblasts,  RPE  (retinal  pigment 
epithelial)  and  NKE  (normal  kidney  epithelial)  cells, 
without protection of MDA-MB-231 breast cancer cells 
with mutant p53. We investigated whether normal cells 
were fully protected and recovered upon removal MI. We 
identified effective combinations of rapamycin with both 
Figure 1: nutlin-3a protects cells by preventing mitotic arrest caused by nocodazole. (A) Drug treatment schedule: MI was added 
1 day after nutlin-3a. 3days later all drugs were washed off and cells were allowed to recover for 6 d and then counted. (B) Selective protection 
of WI-38t, but not MDA-MB-231 cells, from the cytotoxic effect of nocodazole. 10,000 cells were plated per well (in 6 well plates), treated as 
shown in panel A and counted after 6 days.  The results are shown as % of control, in log scale. (C) Prevention of toxic mitotic arrest by non-
toxic G1 and G2 arrest. WI-38-t cells were pre-treated with 2.5 µM nutlin-3a, and then were treated with 200 nM nocodazole. After 24 hours, 
cells were microphotographed (right panel), collected and analyzed by flow cytometry.   Oncotarget 2011; 2:  222 - 233 224 www.impactjournals.com/oncotarget
metformin and nutlin-3a for protection of normal cells 
from MI.
results
Protection of WI-38t cells by nutlin-3a
To evaluate long-term protection, we determined cell 
numbers six days after removal of mitotic inhibitors (MI) 
such as nocodazole and paclitaxel (Fig. 1A). We initially 
used nocodazole (Noco) because it is easily removable by 
washing cell culture. Cells were pretreated with nutlin-3 
and the next day nocodazole was added. After 3 days of 
treatment with nocodazole, cells were washed and cultured 
in the fresh medium for 6 days to allow recovery of the 
protected cells (Fig. 1 A). Nocodazole alone decreased 
cell numbers more than 50-fold compared with control in 
both MDA-MB-231 and WI-38t (Fig. 1B). Pretreatment 
with nutlin-3a did not protect MDA-MB-231 cells, but 
completely prevented the effects of nocodazole in WI-38t 
cells (Fig. 1B). Nutlin-3 caused G1 and G2 arrest (Fig. 
1C). Nocodazole arrested cells with 4N DNA content, 
corresponding to mitotic arrest as evidenced by mitotic/
round cells visualized on live microscopy (Fig. 1C). 
Pretreatment with nutlin-3a (Nu) completely prevented 
nocodazole-induced mitotic arrest (Fig. 1C, Nu+Noco). 
Cell cycle distributions of nutlin-pretreated cells were 
almost identical with (+Noco) and without nocodazole 
(Fig. 1C). Thus, G1 and G2 arrest caused by nutlin-3a 
prevented mitotic arrest caused by nocodazole.
As expected, nutlin-3a induced p53 and p21 (Fig. 
2A). Nocodazole alone induced p53 without inducing p21. 
This is consistent with induction of p53 during prolonged 
mitotic arrest [7, 51, 52]. Isolated induction of p53 
(without induction of p21) by nocodazole is a consequence 
of mitotic arrest [7, 52]. At both concentrations of nutlin-
3a (2.5 µM and 10 µM), cells were completely protected 
from nocodazole: cell numbers were equal after treatment 
with nutlin-3a alone and nutlin-3a plus nocodazole (Fig. 
2B). 
Protection of rPe cells by nutlin-3a
Nutlin-3a also causes reversible arrest in RPE cells, 
so that cells could resume proliferation after nutlin-3a 
was removed [53, 54]. We next investigated whether 
this arrest can protect RPE cells from the toxicity of MI. 
Pretreatment with nutlin-3a partially abrogated the toxicity 
of nocodazole and paclitaxel (Taxol) in RPE cells but not 
in cancer MDA-MB-231 cells with mutant p53 (Fig. 3). 
The effect of paclitaxel (PTX) was less reversible than 
the effect of nocodazole because PTX is poorly washable 
from the cell culture. 
Analysis of cell cycle distribution revealed that 
nutlin-3a  caused  G2  arrest  in  RPE  cells  (Fig.  4).  As 
expected, nocodazole caused mitotic arrest, which was 
indistinguishable from G2 arrest by flow cytometry, but 
was evident by the appearance of mitotic cells (Fig. 4A, 
microphotographs). By arresting cells in G2, nutlin-3a 
prevented mitotic arrest, thus protecting normal cells. In 
contrast, nutlin-3a did not cause arrest in MDA-MB-231 
cells (Fig. 4B). Therefore, nocodazole caused mitotic 
arrest in MDA-MB-231 cells both in the presence and the 
absence of nutlin-3a (Fig. 4B).
Protection of rPe by drug combinations 
Noteworthy,  protection  of  RPE  by  nutlin-3a 
Figure 2: Protective induction of p53/p21 by nutlin-3a in 
WI-38t cells. 
A.  Immunoblot. WI-38t cells were pre-treated with indicated 
concentrations of nutlin-3a (2.5 µM and 10 µM), and then treated with 
200 nM nocodazole. The next day, cells were lysed and immunoblot 
was performed as described in the Methods section. 
b. 50, 000 cells were plated per well (in 6 well plates) and treated as 
shown in Fig. 1A. The results present cell numbers expressed as % 
of control in log scale. Note: Cell numbers in Nutlin+Noco exceeded 
plated cell numbers almost 10-fold, indicating active cell proliferation 
after drug removal (not shown).
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Figure 3: nutlin-3a protects normal retinal pigment epithelial (rPe-19) cells but not MdA-Mb-231 cells.  10,000 cells were 
plated and treated the next day with 2.5 µM nutlin-3a or left untreated. The next day, cells were treated with either 200 nM nocodazole, 50 nM 
Taxol (paclitaxel) or left untreated. Cells were counted 6 days after wash because control cells reached confluence at that time.  The results 
are shown as % of control, in log scale. Note: Nutlin+Noco, final cell numbers exceeded plated cell numbers, indicating cell proliferation after 
drug removal.
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Figure 4: nutlin-3a prevents toxic mitotic arrest by causing non-toxic G2 arrest in rPe cells.  RPE (A) and MDA-MB-231 (B) 
cells were plated in 6-well plates at 50,000/well. Cells were either pretreated with 2.5 µM nutlin-3a or left untreated before addition of 200 nM 
nocodazole. After 24 hours treatment with nocodazole, cells were microphotographed (left panels), collected and analyzed by flow cytometry 
(right panels).   
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Figure 5: cytoprotection of rPe cells with nutlin-3a, rapamycin and metformin 10,000 rPe cells were plated in normal 
(1g/l) glucose medium (panel A) and low (0.5 g/l) glucose medium (panel b). The next day, cells were treated with either 2.5 µM 
nutlin-3a (Nutlin), 1 and 3 mM metformin (M 1 and M 3), 1 nM rapamycin (R) or left untreated. The next day, cells were treated with either 200 
nM nocodazole (Noco) or 50 nM paclitaxel (PTX). 3 days later, the cells were washed and cultured in normal glucose for an additional 10 days 
and then were counted.  The results are shown as % of control (no treatment). Note: in control cells reached confluence during the experiment.
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Figure 6: cytoprotection of WI-38t cells by combining rapamycin and metformin 10,000 WI-38t cells were plated in 
normal glucose medium. The next day, cells were treated with either 1 mM or 3 mM metformin (M 1 and M 3) and 1 nM or 100 nM 
rapamycin (R 1 and R 100) or left untreated (control). The next day, cells were treated with 200 nM nocodazole (Noco) as indicated. After the 3 
days, the cells were washed and cultured for an additional 10 days and then were counted.  The results are shown as % of control (no treatment). 
Note: in control cells reached confluence during the experiment.
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was potentiated by rapamycin, which was slightly 
cytoprotective by itself (Fig. 5 A). Metformin alone was 
marginally protective but its effect was also potentiated by 
rapamycin. A combination of metformin plus rapamycin 
and a combination of nutlin-3a plus rapamycin afforded 
comparable protection. Similar results were obtained in 
low glucose medium (Fig. 5 B). 
Protection of WI-38t by a combination of 
rapamycin and metformin
Next we investigated whether a combination of 
rapamycin and metformin (R+M) can protect WI-38t cells. 
This combination (M + R) afforded 2-3 fold protection 
in WI-38t, but not in MDA-MB-231 cells (Suppl. Fig. 
1). Individually, 3 mM metformin and 1 nM-100 nM 
rapamycin were slightly protective. Combinations of 
metformin with 1 nM rapamycin were more effective (Fig. 
6). We next investigated the mechanism of cytoprotection 
by rapamycin plus metformin (R+M). The combination 
(R+M) caused G1/G2 arrest and this partially prevented 
mitotic arrest caused by nocodazole (Fig. 7). In contrast, 
R+M did not protect MDA-MB-231 cells (Fig. 7). 
Noteworthy, the R+M combination was toxic to MDA-
MB-231 cells cultured at low glucose (Suppl. Fig. 2).
comparison of M+r and nutlin-3a in nKe cells
We next tested whether these combinations were 
protective in a third type of normal cells. Normal kidney 
epithelial  (NKE)  cells  were  partially  protected  from 
nocodazole and paclitaxel (PTX) in both normal and 
low glucose media. Combinations of nutlin-3a with 
rapamycin (N+R), even though rapamycin alone was not 
protective, were the most effective in NKE cells (Fig. 8). 
Combinations of metformin with rapamycin (R+M) were 
moderately protective (Fig. 8).
Figure 7: A combination of rapamycin and metformin prevents mitotic arrest in WI-38t cells. 50,000 WI-38t and MDA-
MB-231 cells were plated in 6-well plates and pre-treated with a combination of 100 nM rapamycin and 3 mM  metformin (R+M).  The next 
day, cells were treated with 200 nM nocodazole. After 24 hours, cells were microphotographed (left panels), collected and flow cytometry was 
performed (right panels).   
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dIscussIon
The goal of chemotherapeutic cyclotherapy is 
selective protection of normal cells by exploiting 
aberrations in cancer cell cycle such as loss of p53 [13, 
55-57]. By causing G1 and G2 arrest, nutlin-3a protects 
cells with wt p53 from mitotic inhibitors. As a proof of 
principle in paired cell lines, nutlin-3a prevented mitotic 
arrest, cell death or polyploidization (a short-term 
protection) [16, 17, 21, 22]. Furthermore, pretreatment 
with nutlin-3a allowed normal skin-derived fibroblasts to 
recover from MI treatment, as measured by an increase 
in cell numbers after 6 days (a long-term protection) 
in drug-free medium [21]. Here we focused on a long-
term protection and extended this observation to WI-38 
fibroblasts and two epithelial cell lines: RPE and NKE. 
As expected, nutlin-3a arrested normal cells in both G1 
and/or G2 (depending on cell type) and thus protected 
them from mitotic arrest caused by MI. While affording 
a long-term protection to all 3 normal cell types, nutlin-
3a did not protect MDA-MB-231 cancer cells in any 
experiments. Similar results in normal cell lines of 
different origin indicate that nutlin-3a might also protect 
relevant normal cells in the organism. Remarkably, Sur et 
al demonstrated that oral administration of Nutlin-3 (200 
mg/kg) efficiently protected mice from neutropenia caused 
by a mitotic inhibitor [20]. This important result indicates 
that protection in cell culture is indeed applicable to the 
organism.
We found that rapamycin further potentiated 
the protective effect of nutlin-3a in three cell lines, 
most  robustly  in  NKE  cells.  There  are  two  potential 
mechanisms. First, rapamycin, as a mild cytostatic agent, 
may increase the durability of arrest, thus potentiating 
the protection. Second, to be protective in a long-term, 
the arrest must be reversible. Nutlin-3-induced arrest is 
mostly reversible in most cell lines [58, 59]. But nutlin-3a 
can also induce irreversible senescence, depending on the 
activity of mTOR, p53 levels and the duration of the arrest 
[53, 54, 60]. Rapamycin may improve the reversibility of 
arrest caused by p53 [53]. We are currently investigating 
the mechanism of potentiation of nutlin-3a by rapamycin 
(Leontieva et al, MS in preparation). 
Since nutlin-3a does not cause arrest in cancer cells 
lacking p53, the addition of rapamycin cannot possibly 
potentiate nutlin-3a in cells with mutant p53. Therefore, 
like nutlin-3a alone, a combination of nutlin-3a plus 
rapamycin (N+R) does not protect cancer cells with 
mutant p53. Therefore, the combination of nutlin-3a plus 
rapamycin can be used for protection of normal cells in 
Figure 8: Protection of nKe cells from nocodazole and paclitaxel in normal glucose and low glucose. 10,000 NKE cells were 
plated in either 1g/L glucose or 0.5g/L glucose (low). Cells were pre-treated for 24 hrs with either 2.5 µM nutlin-3a, 1 and 10 nM rapamycin (R1 
and R10), 3 mM metformin (M) alone or in combination and then were treated with either 200 nM nocodazole (Noco) or 50 nM Taxol (PTX). 
After 3 days, cells were washed and cultured for 6 days in fresh medium before counting.
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patients having tumors with mutant p53. In heterogeneous 
tumors with co-existing cells having wt and mutant p53, 
the N+R combination may spare cancer cells with wt p53. 
This will revert the tumor to a less aggressive phenotype, 
which is more sensitive to conventional chemotherapy. 
Therefore, a combination of N+R+MI may be promising 
in heterogeneous cancers too.
It was shown that fasting, which decreases 
levels of glucose and insulin and inactivates nutrient-
sensing signaling pathways, decreases side-effects of 
chemotherapy [29]. Like fasting, metformin, an anti-
diabetic drug, decreases glucose levels. Also, metformin 
lowers levels of insulin in women with early breast cancer 
[38]. Furthermore, metformin decreases tumor growth 
in mice fed by high-calorie diet [61, 62]. Metformin and 
rapamycin differently affects nutrient-sensing pathways 
[63]. Therefore, 2 drugs may in theory potentiate each 
other. A combination of temsirolimus (an analog of 
rapamycin) and metformin showed promising results in 
phase I clinical trial as cancer therapy [43, 64].
Here we demonstrated that a combination of 
rapamycin and metformin (R+M) caused protective G1 and 
G2 arrest in normal cells. Furthermore, this combination 
provided a long-term protection against MI in all three 
normal cell types. Not only did the R+M combination not 
protect cancer cells but, in contrast, it was toxic by itself 
to MDA-MB-231 cells in low glucose conditions. Low 
glucose levels are toxic to cancer cells, which depend on 
glucose as substrates for their glycolytic phenotype [65-
72]. Noteworthy, metformin decreases glucose levels in 
the organism. 
Metformin enhances susceptibility of p53-/- cells 
to apoptosis upon nutrient deprivation [73]. In contrast, 
p53-proficient cells can undergo cell cycle arrest (instead 
of apoptosis) in low glucose [74]. This explains selective 
toxicity of metformin to p53-deficient cells in low glucose 
[73, 74] observed in our study too. Thus a combination of 
metformin, rapamycin and fasting may be toxic to cancer 
cells, while protecting normal cells from chemotherapy 
with MI (Fig. 9), thus increasing therapeutic window. 
Concentrations of metformin (1 mM) and rapamycin 
(1 nM) are lower than those achievable in patients 
[75-80]. We suggest that metformin and rapamycin 
should be administrated for a 1-2-day period prior and 
simultaneously with MI such as the Vinca drugs and 
Taxanes (Fig. 10). In conclusion, based on cell culture data 
and analysis of the literature, we suggest that nutlin-3a, 
nutlin-3a plus rapamycin and rapamycin plus metformin 
may extend the therapeutic window of microtubule-active 
chemotherapy. Low concentrations of rapamycin and 
metformin, especially combined with fasting, may be 
used in the clinic today. 
Methods And MAterIAls
cell culture
Cells were cultured in RPMI media purchased from 
Cellgro (Manassas, VA) supplemented with 5% (v/v) 
FBS. Rapamycin was purchased from LC Laboratory 
(Woburn, MA), and metformin, nutlin-3a, nocodazole 
and paclitaxel were from Sigma-Aldrich (St. Louis, 
MO, USA). Glucose was added to glucose-free RPMI 
Metformin
Rapamycin
Low glucose MI
normal
cell
RAPA +
metformin
Chemo
(MI)
RAPA +
metformin
Chemo
(MI)
days
Figure 10: Proposal for potential clinical trials
Figure 9: cyclotherapy: protection of normal cells and 
unshielding of cancer cells.Oncotarget 2011; 2:  222 - 233 230 www.impactjournals.com/oncotarget
to desired concentrations or mixed in ratios using RPMI 
with glucose (2 g/L) and RPMI without glucose. WI-38, 
WI-38t fibroblasts immortalized by telomerase and retinal 
pigment epithelial (RPE) ARPE-19 cells were described 
previously [81], [59]. MDA-MB-231 was from ATCC 
(Manassas, VA). Normal Kidney Epithelial (NKE) cells 
were provided by Dr. Katerina V. Gurova (RPCI).
Flow cytometry
Cells were fixed in 70% ethanol and stained with 
25 μg/ml propidium iodide (PI), 0.2% Triton X- 100 and 
40 μg/ml RNase in PBS. Flow cytometry was performed 
using FACScan, Becton Dickinson, San Jose, CA with 
10,000-20,000 events per sample. Cell cycle distribution 
was analyzed using Modfit LT software (Verity Software 
House  Inc.,  Topsham,  ME)  with  histograms  of  DNA 
content profiles on the X-axis and cell numbers on the 
y-axis.
Mitotic Index
Following flow cytometry, propidium iodine stained 
nuclei were visualized on coverslips and mitotic cells 
were identified by morphological characteristics allowing 
G2 phase verses mitotic cells to be distinguished. Cells 
were photographed on a Zeiss Axioplan 2 microscope 
(Thornwood, NY).
cell counting
Cells were counted on Vicell Series Cell Viability 
Analyzer (Beckman Coulter, Inc., Brea, CA) using Trypan 
Blue exclusion method to provide a proportion of live and 
dead cells.
Immunoblot analysis
Immunoblot was performed as described previously 
[53]. The following antibodies were used: mouse anti-p53 
(Ab-6) from Oncogene, mouse anti-p21 from BD 
Biosciences (San Jose, CA); rabbit anti-actin from Sigma-
Aldrich (St. Louis, MO); secondary goat anti-rabbit and 
goat antimouse HRP conjugated antibodies were from 
Chemicon (Billerica, MA) and Bio-Rad (St. Louis, MO), 
respectively.
reFerences
1.  Blagosklonny MV. Analysis of FDA approved anticancer 
drugs reveals the future of cancer therapy. Cell Cycle. 
2004; 3:1035-1042.
2.  Jordan MA. Mechanism of action of antitumor drugs that 
interact with microtubules and tubulin. Curr Med Chem 
Anticancer Agents. 2002; 2:1-17.
3.  Rowinsky EK, Calvo E. Novel agents that target tublin and 
related elements. Semin Oncol. 2006; 33:421-435.
4.  Morris PG, Fornier MN. Microtubule active agents: beyond 
the taxane frontier. Clin Cancer Res. 2008; 14:7167-7172.
5.  Perez EA. Microtubule inhibitors: Differentiating tubulin-
inhibiting agents based on mechanisms of action, clinical 
activity, and resistance. Mol Cancer Ther. 2009; 8:2086-
2095.
6.  Jordan MA, Thrower D, Wilson L. Mechanism of inhibition 
of cell proliferation by Vinca alkaloids. Cancer Res. 1991; 
51:2212-2222.
7.  Demidenko ZN, Kalurupalle S, Hanko C, Lim CU, Broude 
E, Blagosklonny MV. Mechanism of G1-like arrest by low 
concentrations of paclitaxel: next cell cycle p53-dependent 
arrest with sub G1 DNA content mediated by prolonged 
mitosis. Oncogene. 2008; 27:4402-4410.
8.  Blagosklonny MV. Mitotic arrest and cell fate: why and 
how mitotic inhibition of transcription drives mutually 
exclusive events. Cell Cycle. 2007; 6:70-74.
9.  Bekier ME, Fischbach R, Lee J, Taylor WR. Length of 
mitotic arrest induced by microtubule-stabilizing drugs 
determines cell death after mitotic exit. Mol Cancer Ther. 
2009; 8:1646-1654.
10.  Vogelstein  B,  Lane  DP,  Levine  AJ.  Surfing  the  p53 
network. Nature. 2000; 408:307-310.
11.  Blagosklonny  MV,  Pardee  AB.  Exploiting  cancer  cell 
cycling for selective protection of normal cells. Cancer Res. 
2001; 61:4301-4305.
12.  Blagosklonny MV. Matching targets for selective cancer 
therapy. Drug Discov Today. 2003; 8:1104-1107.
13.  Blagosklonny MV. “Targeting the absence” and therapeutic 
engineering for cancer therapy. Cell Cycle. 2008; 7:1307-
1312.
14.  Blagosklonny MV, Robey R, Bates S, Fojo T. Pretreatment 
with DNA-damaging agents permits selective killing of 
checkpoint-deficient cells by microtubule-active drugs. J 
Clin Invest. 2000; 105:533-539.
15.  Blagosklonny MV. Sequential activation and inactivation 
of G2 checkpoints for selective killing of p53-deficient cells 
by microtubule-active drugs. Oncogene. 2002; 21:6249-
6254.
16.  Choong  ML,  Yang  H,  Lee  MA,  Lane  DP.  Specific 
activation of the p53 pathway by low dose actinomycin D: 
A new route to p53 based cyclotherapy. Cell Cycle. 2009; 
8:2810-8
17. Rao B, van Leeuwen IMM, Higgins M, Campbel J, 
Thompson AM, Lane DP, Lain S, 639-650 p. Evaluation 
of an Actinomycin D/VX-680 aurora kinase inhibitor 
combination in p53-based cyclotherapy. Oncotarget. 2010; 
1:639-650.
18.  Vassilev LT. Small-molecule antagonists of p53-MDM2 
binding: research tools and potential therapeutics. Cell Oncotarget 2011; 2:  222 - 233 231 www.impactjournals.com/oncotarget
Cycle. 2004; 3:419-421.
19.  Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, 
Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, 
Fotouhi N, Liu EA. In vivo activation of the p53 pathway 
by small-molecule antagonists of MDM2. Science. 2004; 
303:844-848.
20.  Sur S, Pagliarini R, Bunz F, Rago C, Diaz LA, Jr., Kinzler 
KW, Vogelstein B, Papadopoulos N. A panel of isogenic 
human cancer cells suggests a therapeutic approach for 
cancers with inactivated p53. Proc Natl Acad Sci U S A. 
2009; 106:3964-3969.
21.  Carvajal D, Tovar C, Yang H, Vu BT, Heimbrook DC, 
Vassilev LT. Activation of p53 by MDM2 antagonists can 
protect proliferating cells from mitotic inhibitors. Cancer 
Res. 2005; 65:1918-1924.
22.  Cheok CF, Kua N, Kaldis P, Lane DP. Combination of 
nutlin-3 and VX-680 selectively targets p53 mutant cells 
with reversible effects on cells expressing wild-type p53. 
Cell Death Differ. 2010:1486-1500.
23.  Vogelstein B, Kinzler KW. Cancer genes and the pathways 
they control. Nat Med. 2004; 10:789-799.
24.  Kang S, Bader AG, Zhao L, Vogt PK. Mutated PI 3-kinases: 
cancer targets on a silver platter. Cell Cycle. 2005; 4:578-
581.
25.  Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling 
controls tumour cell growth. Nature. 2006; 441:424-430.
26.  Guertin DA, Sabatini DM. Defining the role of mTOR in 
cancer. Cancer Cell. 2007; 12:9-22.
27.  Blagosklonny MV, Darzynkiewicz Z. Four birds with one 
stone: RAPA as potential anticancer therapy. Cancer Biol 
Ther. 2002; 1:359-361.
28.  Raffaghello L, Lee C, Safdie FM, Wei M, Madia F, Bianchi 
G, Longo VD. Starvation-dependent differential stress 
resistance protects normal but not cancer cells against 
high-dose chemotherapy. Proc Natl Acad Sci U S A. 2008; 
105:8215-8220.
29.  Raffaghello L, Safdie F, Bianchi G, Dorff T, Fontana 
L, Longo VD. Fasting and differential chemotherapy 
protection in patients. Cell Cycle. 2010; 9:4474-4476.
30. Lee C, Safdie FM, Raffaghello L, Wei M, Madia F, 
Parrella E, Hwang D, Cohen P, Bianchi G, Longo VD. 
Reduced levels of IGF-I mediate differential protection of 
normal and cancer cells in response to fasting and improve 
chemotherapeutic index. Cancer Res. 2010; 70:1564-1572.
31.  Safdie FM, Dorff T, Quinn D, Fontana L, Wei M, Lee 
C, Cohen P, Longo VD. Fasting and cancer treatment in 
humans: A case series report. Aging. 2009; 1:988-1007.
32.  Tremblay F, Marette A. Amino acid and insulin signaling 
via the mTOR/p70 S6 kinase pathway. A negative feedback 
mechanism leading to insulin resistance in skeletal muscle 
cells. J Biol Chem. 2001; 276:38052-38060.
33.  Tremblay F, Krebs M, Dombrowski L, Brehm A, Bernroider 
E, Roth E, Nowotny P, WaldhŠusl W, Marette A, Roden 
M. Overactivation of S6 kinase 1 as a cause of human 
insulin resistance during increased amino acid availability. 
Diabetes. 2005; 54:2674-2684.
34. Shah OJ, Hunter T. Tuberous sclerosis and insulin 
resistance. Unlikely bedfellows reveal a TORrid affair. Cell 
Cycle. 2005; 4:46-51.
35.  Khamzina L, Veilleux A, Bergeron S, Marette A. Increased 
activation of the mammalian target of rapamycin pathway in 
liver and skeletal muscle of obese rats: possible involvement 
in obesity-linked insulin resistance. Endocrinology. 2005; 
146:1473-1481.
36.  Tzatsos A, Kandror KV. Nutrients suppress 
phosphatidylinositol 3-kinase/Akt signaling via raptor-
dependent mTOR-mediated insulin receptor substrate 1 
phosphorylation. Mol Cell Biol. 2006; 26:63-76.
37.  Krebs M, Brunmair B, Brehm A, Artwohl M, Szendroedi 
J,  Nowotny  P,  Roth  E,  FŸrnsinn  C,  Promintzer  M, 
Anderwald C, Bischof M, Roden M. The Mammalian 
target of rapamycin pathway regulates nutrient-sensitive 
glucose uptake in man. Diabetes. 2007; 56:1600-1607.
38.  Goodwin PJ, Pritchard KI, Ennis M, Clemons M, Graham 
M, Fantus IG. Insulin-lowering effects of metformin in 
women with early breast cancer. Clin Breast Cancer. 2008; 
8:501-505.
39.  Berstein LM. Modern approach to metabolic rehabilitation 
of cancer patients: biguanides (phenformin and metformin) 
and beyond. Future Oncol. 2010; 6:1313-1323.
40.  Erdemoglu E, Guney M, Giray SG, Take G, Mungan T. 
Effects of metformin on mammalian target of rapamycin 
in a mouse model of endometrial hyperplasia. Eur J Obstet 
Gynecol Reprod Biol. 2009; 145:195-199.
41.  Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg 
N. Metformin inhibits mammalian target of rapamycin-
dependent translation initiation in breast cancer cells. 
Cancer Res. 2007; 67:10804-10812.
42.  Vazquez-Martin A, Oliveras-Ferraros C, Menendez JA. 
The antidiabetic drug metformin suppresses HER2 (erbB-
2) oncoprotein overexpression via inhibition of the mTOR 
effector p70S6K1 in human breast carcinoma cells. Cell 
Cycle. 2009; 8:88-96.
43. Vazquez-Martin A, Oliveras-Ferraros C, del Barco S, 
Martin-Castillo B, Menendez JA. mTOR inhibitors and 
the anti-diabetic biguanide metformin: new insights into 
the molecular management of breast cancer resistance to 
the HER2 tyrosine kinase inhibitor lapatinib (Tykerb). Clin 
Transl Oncol. 2009; 11:455-459.
44. Hudes GR. Targeting mTOR in renal cell carcinoma. 
Cancer. 2009; 115:2313-2320.
45.  Janes MR, Fruman DA. Targeting TOR dependence in 
cancer. Oncotarget. 2010; 1:69-76.
46.  Marimpietri D, Brignole C, Nico B, Pastorino F, Pezzolo A, 
Piccardi F, Cilli M, Di Paolo D, Pagnan G, Longo L, Perri 
P, Ribatti D, Ponzoni M. Combined therapeutic effects 
of vinblastine and rapamycin on human neuroblastoma 
growth, apoptosis, and angiogenesis. Clin Cancer Res. Oncotarget 2011; 2:  222 - 233 232 www.impactjournals.com/oncotarget
2007; 13:3977-3988.
47.  Ramalingam SS, Harvey RD, Saba N, Owonikoko TK, 
Kauh J, Shin DM, Sun SY, Strychor S, Tighiouart M, Egorin 
MJ, Fu H, Khuri FR. Phase 1 and pharmacokinetic study 
of everolimus, a mammalian target of rapamycin inhibitor, 
in combination with docetaxel for recurrent/refractory 
nonsmall cell lung cancer. Cancer. 2010; 116:3903-3909.
48.  Andre F, Campone M, O’Regan R, Manlius C, Massacesi 
C, Sahmoud T, Mukhopadhyay P, Soria JC, Naughton 
M, Hurvitz SA. Phase I study of everolimus plus weekly 
paclitaxel and trastuzumab in patients with metastatic 
breast cancer pretreated with trastuzumab. J Clin Oncol. 
28:5110-5115.
49.  Perotti A, Locatelli A, Sessa C, Hess D, Vigano L, Capri 
G, Maur M, Cerny T, Cresta S, Rojo F, Albanell J, Marsoni 
S, Corradino I, Berk L, Rivera VM, Haluska F et al. 
Phase IB study of the mTOR inhibitor ridaforolimus with 
capecitabine. J Clin Oncol. 28:4554-4561.
50.  Sessa C, Tosi D, Vigano L, Albanell J, Hess D, Maur M, 
Cresta S, Locatelli A, Angst R, Rojo F, Coceani N, Rivera 
VM, Berk L, Haluska F, Gianni L. Phase Ib study of weekly 
mammalian target of rapamycin inhibitor ridaforolimus 
(AP23573; MK-8669) with weekly paclitaxel. Ann Oncol. 
21:1315-1322.
51.  Giannakakou P, Robey R, Fojo T, Blagosklonny MV. Low 
concentrations of paclitaxel induce cell type-dependent p53, 
p21 and G1/G2 arrest instead of mitotic arrest: molecular 
determinants of paclitaxel-induced cytotoxicity. Oncogene. 
2001; 20:3806-3813.
52. Blagosklonny MV. Prolonged mitosis versus tetraploid 
checkpoint: how p53 measures the duration of mitosis. Cell 
Cycle. 2006; 5:971-975.
53. Leontieva O, Gudkov A, Blagosklonny M. Weak p53 
permits senescence during cell cycle arrest. Cell Cycle. 
2010; 9:4323-4327.
54.  Korotchkina LG, Leontieva OV, Bukreeva EI, Demidenko 
ZN, Gudkov AV, Blagosklonny MV. The choice between 
p53-induced senescence and quiescence is determined in 
part by the mTOR pathway. Aging (Albany NY). 2010; 
2:344-352.
55. Blagosklonny MV, Darzynkiewicz Z. Cyclotherapy: 
Protection of normal cells and unshielding of cancer cells. 
Cell Cycle. 2002; 1:375-382.
56. Brown CJ, Lain S, Verma CS, Fersht AR, Lane DP. 
Awakening guardian angels: drugging the p53 pathway. 
Nat Rev Cancer. 2009; 9:862-873.
57.  Lane DP, Cheok CF, Lain S. p53-based cancer therapy. 
Cold Spring Harb Perspect Biol. 2010; 2:a001222.
58.  Huang B, Deo D, Xia M, Vassilev LT. Pharmacologic 
p53 Activation Blocks Cell Cycle Progression but Fails to 
Induce Senescence in Epithelial Cancer Cells. Mol Cancer 
Res. 2009; 7:1497-1509.
59.  Korotchkina LG, Demidenko ZN, Gudkov AV, 
Blagosklonny MV. Cellular quiescence caused by the 
Mdm2 inhibitor nutlin-3a. Cell Cycle. 2009; 8:3777-3781.
60.  Efeyan A, Ortega-Molina A, Velasco-Miguel S, Herranz 
D, Vassilev LT, Serrano M. Induction of p53-dependent 
senescence by the MDM2 antagonist nutlin-3a in mouse 
cells of fibroblast origin. Cancer Res. 2007; 67:7350-7357.
61.  Algire C, Zakikhani M, Blouin MJ, Shuai JH, Pollak M. 
Metformin attenuates the stimulatory effect of a high-
energy diet on in vivo LLC1 carcinoma growth. Endocr 
Relat Cancer. 2008; 15:833-839.
62.  Algire C, Amrein L, Zakikhani M, Panasci L, Pollak M. 
Metformin blocks the stimulative effect of a high-energy 
diet on colon carcinoma growth in vivo and is associated 
with  reduced  expression  of  fatty  acid  synthase.  Endocr 
Relat Cancer. 2010; 17:351-360.
63.  Zakikhani M, Blouin MJ, Piura E, Pollak MN. Metformin 
and rapamycin have distinct effects on the AKT pathway 
and proliferation in breast cancer cells. Breast Cancer Res 
Treat. 2010; 123:271-279.
64.  Mackenzie MJ, Ernst S, Johnson C, Winquist E. A phase 
I study of temsirolimus and metformin in advanced solid 
tumours. Invest New Drugs. in press
65.  Shaw RJ, Kosmatka M, Bardeesy N, Hurley RL, Witters 
LA, DePinho RA, Cantley LC. The tumor suppressor 
LKB1 kinase directly activates AMP-activated kinase and 
regulates apoptosis in response to energy stress. Proc Natl 
Acad Sci U S A. 2004; 101:3329-3335.
66.  Gatenby RA, Gillies RJ. Why do cancers have high aerobic 
glycolysis? Nat Rev Cancer. 2004; 4:891-899.
67.  Hsu PP, Sabatini DM. Cancer cell metabolism: Warburg 
and beyond. Cell. 2008; 134:703-707.
68.  Yeluri S, Madhok B, Prasad KR, Quirke P, Jayne DG. 
Cancer’s craving for sugar: an opportunity for clinical 
exploitation. J Cancer Res Clin Oncol. 2009; 135:867-877.
69.  Young CD, Anderson SM. Sugar and fat - that’s where it’s 
at: metabolic changes in tumors. Breast Cancer Res. 2008; 
10:202.
70.  Diaz-Ruiz R, Uribe-Carvajal S, Devin A, Rigoulet M. 
Tumor cell energy metabolism and its common features 
with yeast metabolism. Biochim Biophys Acta. 2009; 
1796:252-265.
71.  Kim JW, Dang CV. Cancer’s molecular sweet tooth and the 
Warburg effect. Cancer Res. 2006; 66:8927-8930.
72.  Bui T, Thompson CB. Cancer’s sweet tooth. Cancer Cell. 
2006; 9:419-420.
73.  Buzzai M, Jones RG, Amaravadi RK, Lum JJ, DeBerardinis 
RJ, Zhao F, Viollet B, Thompson CB. Systemic treatment 
with the antidiabetic drug metformin selectively impairs 
p53-deficient  tumor  cell  growth.  Cancer  Res.  2007; 
67:6745-6752.
74.  Jones RG, Plas DR, Kubek S, Buzzai M, Mu J, Xu Y, 
Birnbaum MJ, Thompson CB. AMP-activated protein 
kinase induces a p53-dependent metabolic checkpoint. Mol 
Cell. 2005; 18:283-293.
75.  Dell’Aglio DM, Perino LJ, Kazzi Z, Abramson J, Schwartz Oncotarget 2011; 2:  222 - 233 233 www.impactjournals.com/oncotarget
MD, Morgan BW. Acute metformin overdose: examining 
serum pH, lactate level, and metformin concentrations in 
survivors versus nonsurvivors: a systematic review of the 
literature. Ann Emerg Med. 2009; 54:818-823.
76. Mahalati K, Kahan BD. Clinical pharmacokinetics of 
sirolimus. Clin Pharmacokinet. 2001; 40:573-585.
77.  Rodriguez  AE,  Rodriguez  Alemparte  M,  Vigo  CF, 
Fernandez Pereira C, Llaurado C, Vetcher D, Pocovi A, 
Ambrose J. Role of oral rapamycin to prevent restenosis in 
patients with de novo lesions undergoing coronary stenting: 
results of the Argentina single centre study (ORAR trial). 
Heart. 2005; 91:1433-1437.
78.  Cloughesy TF, Yoshimoto K, Nghiemphu P, Brown K, 
Dang J, Zhu S, Hsueh T, Chen Y, Wang W, Youngkin D, 
Liau L, Martin N, Becker D, Bergsneider M, Lai A, Green 
R et al. Antitumor activity of rapamycin in a Phase I trial 
for  patients  with  recurrent  PTEN-deficient  glioblastoma. 
PLoS Med. 2008; 5:e8.
79. Boehm A, Mayerhofer M, Herndlhofer S, Knoebl P, 
Sillaber C, Sperr WR, Jaeger U, Valent P. Evaluation of 
in vivo antineoplastic effects of rapamycin in patients with 
chemotherapy-refractory AML. Eur J Intern Med. 2009; 
20:775-778.
80.  Armstrong AJ, Netto GJ, Rudek MA, Halabi S, Wood 
DP, Creel PA, Mundy K, Davis SL, Wang T, Albadine 
R, Schultz L, Partin AW, Jimeno A, Fedor H, Febbo PG, 
George DJ et al. A pharmacodynamic study of rapamycin 
in men with intermediate- to high-risk localized prostate 
cancer. Clin Cancer Res. 2010; 16:3057-3066.
81.  Demidenko ZN, Blagosklonny MV. Growth stimulation 
leads to cellular senescence when the cell cycle is blocked. 
Cell Cycle. 2008; 7:3355-3361.